US Court Finally Approves Bayer’s Settlement of Up to $7.25 Billion in Roundup Glyphosate Lawsuits
This article was translated from Arabic. Read the Arabic original
Austria Now News, Leverkusen: A US court has given final approval to the class-action settlement reached by the German chemical and pharmaceutical company Bayer with plaintiffs’ representatives in the dispute over potential cancer risks from the glyphosate-based weed killer Roundup, worth up to $7.25 billion.
The Judge’s Decision
Judge Timothy Boyer in the US state of Missouri fully approved the agreement, writing in his ruling that the settlement is fair, reasonable, and appropriate. The settlement is intended to provide compensation for tens of thousands of affected individuals.
The settlement was negotiated last February and provides for payments spanning a period of up to 21 years. According to Bayer, it is intended to resolve all lawsuits related to claims of non-Hodgkin lymphoma.
Company Stance
Bayer CEO Bill Anderson described the court’s final approval as a crucial milestone in the company’s multi-pronged strategy to reduce current and future glyphosate lawsuits, emphasizing that the settlement does not constitute any admission of guilt.
Last June, Bayer won a landmark case before the US Supreme Court, after which ruling lawsuits against the company based on the absence of cancer warnings on herbicide packaging are fundamentally no longer possible.
Case Background
Bayer acquired the US Roundup manufacturer Monsanto in 2018 and has since spent billions on legal disputes. Glyphosate is classified as a potential carcinogen, and tens of thousands of people have filed lawsuits as a result, while Bayer relies on studies and official approvals that it says prove the substance’s safety.
Austria Now News, always bringing you the latest updates.
Image: Atamari / Wikimedia Commons, CC BY-SA 3.0, and Circle: Plant pests and diseases / Flickr, CC0